Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Rhabdomyosarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Multiple Endocrine Neoplasia Type 2a 1 Medulloblastoma 1 Lethal Congenital Contracture Syndrome 2 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 15 Temozolomide 11 Vincristine 10 Magnetic Resonance Spectroscopy 10 Cisplatin 10 Specimen Handling 8 Radiotherapy 8 Etoposide 8 X-Rays 6 Phantoms, Imaging 6 Carboplatin 6 Nuclear Medicine Department, Hospital 5 Lomustine 5 Radiation 4 Platinum 4 Methotrexate 4 Irinotecan 4 Filgrastim 4 Biopsy 4 1,2-diaminocyclohexaneplatinum II citrate 4 etoposide phosphate 3 Thiotepa 3 Nivolumab 3 Granulocyte Colony-Stimulating Factor 3 Celecoxib 3 Bevacizumab 3 Automobiles 3 ulixertinib 2 tipifarnib 2 tazemetostat 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Medulloblastoma × Vascular Endothelial Growth Factor A × 1 year × Clear all

NCT07346157 2026-06-01

PNOC044

University of California, San Francisco

Phase 1/2 Not yet recruiting

Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡